# Zevorcabtagene autoleucel

Source: https://onco.cc/drugs/zevorcabtagene-autoleucel/  
OnCo record `zevorcabtagene-autoleucel` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Zevor-cel is CARsgen's myeloma CAR-T, approved in China in 2024 for patients whose disease has come back after three or more treatments.

## Summary

Approved by the NMPA in February 2024 for relapsed or refractory multiple myeloma after three or more lines including a proteasome inhibitor and an immunomodulatory drug, on the LUMMICAR STUDY 1 phase 1/2 trial run in China. CARsgen reported high response rates with deep remissions and mostly low-grade cytokine release syndrome; the full phase 2 report appeared in Experimental Hematology and Oncology in 2025. Commercialised in China with Huadong Medicine. CARsgen's second approval, satricabtagene autoleucel for Claudin 18.2-positive gastric cancer, followed in 2025.

## Fields

- Kind: Treatment
- Status: approved
- Last checked: 2026-09-10
- Tags: china
- Brand: Saikaize
- Code: zevor-cel, CT053
- Modality: Cell therapy (autologous BCMA CAR-T, fully human binder)
- Mechanism: Autologous T cells transduced with a fully human anti-BCMA CAR (4-1BB co-stimulation) developed by CARsgen from its Shanghai platform.
- Approvals: China 2024: Relapsed or refractory multiple myeloma after three or more lines including a proteasome inhibitor and an immunomodulatory agent

## Sources

- CARsgen Therapeutics: https://www.carsgen.com/en/
- Phase 2 study of zevorcabtagene autoleucel (Exp Hematol Oncol 2025): https://doi.org/10.1186/s40164-025-00710-y
- Zevorcabtagene autoleucel: first approval (Mol Diagn Ther 2024): https://doi.org/10.1007/s40291-024-00723-z

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- technologies: [CAR-T cell therapy](https://onco.cc/technologies/car-t/)
- targets: [BCMA](https://onco.cc/targets/bcma/)
- companies: [CARsgen Therapeutics](https://onco.cc/companies/carsgen/)
- trials: [Clinical Trial to Evaluate Zevor-cel (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2)](https://onco.cc/trials/nct03915184/), [LUMMICAR STUDY 1](https://onco.cc/trials/lummicar-1/)
- key papers: [Phase II study of zevorcabtagene autoleucel, a fully human BCMA-targeting CAR T cell therapy, in patients with relapsed/refractory multiple myeloma](https://onco.cc/key-papers/paper-chen-exp-hematol-oncol/), [Zevorcabtagene Autoleucel: First Approval](https://onco.cc/key-papers/paper-dhillon-mol-diagn-ther/)
- people: [Zonghai Li](https://onco.cc/people/li-zonghai/)
- institutions: [Renji Hospital, Shanghai Jiao Tong University](https://onco.cc/institutions/renji-hospital/)

---
JSON: https://onco.cc/api/v1/entities/zevorcabtagene-autoleucel.json